Repertoire Immune Medicines
3 known investors
Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Founders & leadership
TS
Torben Straight NissenChief Executive Officer
AC
Anthony CoylePresident, Research and Development
RA
Robert AndtbackaChief Medical Officer
JD
John DelyaniChief Business Officer
JK
Jan KisielowChief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.
Investors · 3
In the news
Frequently asked questions
- What does Repertoire Immune Medicines do?
- Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.
- Who are Repertoire Immune Medicines's investors?
- Repertoire Immune Medicines's investors include Flagship Pioneering, SoftBank Vision Fund, JDRF T1D Fund.